Adjuvant, Salvage PCa Radiotherapy Long-Term Outcomes Similar
New analysis shows no significant difference in 10-year progression-free and overall survival among men with high-risk prostate cancer.
Adjuvant and salvage radiotherapy after radical prostatectomy for high-risk prostate cancer (PCa) is associated with similar long-term progression-free and overall survival, according to a new study.
Investigators at Pusan National University School of Medicine in Busan, Korea, led by Hong Koo Ha, MD, conducted a systemic review and meta-analysis of 7 studies comparing adjuvant radiotherapy (ART) and salvage radiotherapy (SRT). The studies included a total of 2,380 patients with locally advanced PCa or who had adverse pathologic features, such as positive surgical margins and high Gleason scores. Of these patients, 1,192 received ART and 1,188 received SRT.
Compared with SRT, ART was associated with a 39% and 30% lower 5- and 10-year biochemical recurrence risk, respectively, the investigators reported in the Korean Journal of Urology (2015;56:735-741). ART was associated with a 36% decreased risk of progression at 5 years, but progression rates were similar at 10 years. The researchers found no significant difference in 5- and 10-year overall survival.